REFRACTORY NON-HODGKIN LYMPHOMA

This study tested a drug called nivolumab in 20 adults with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab helps the immune system attack cancer cells. The goal was to see if it could shrink tumors or slow …

This early-phase study tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…

This study tested a drug called samotolisib in 18 children and teens whose cancers had spread, come back, or stopped responding to treatment. The drug works by blocking certain enzymes that cancer cells need to grow. The goal was to see if the drug could shrink or stop the cancer…

This study tested the drug palbociclib in 23 children and young adults (ages 1-21) whose cancers had come back or stopped responding to treatment. The drug works by blocking certain proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the di…

This study tested whether adding the drug anakinra to standard CAR-T cell therapy could reduce serious brain side effects in people with relapsed or refractory non-Hodgkin lymphoma. Fifteen participants received the combination. The goal was to see if anakinra could lower the rat…

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2 or SWI/SNF) in their tumors. The goal was to see if the drug could shrink or control the cancer. This is a dise…

This study tested a combination of pembrolizumab (an immunotherapy drug) and targeted radiation in 17 patients with non-Hodgkin lymphoma that had returned or stopped responding to treatment. The goal was to see if adding radiation could help the immune system fight the cancer bet…